Drug Profile


Alternative Names: INCB-024360; INCB-24360

Latest Information Update: 11 Jan 2017

Price : $50

At a glance

  • Originator Incyte Corporation
  • Developer Incyte Corporation; MedImmune; Merck AG
  • Class Amides; Antineoplastics; Imides; Oxadiazoles; Small molecules
  • Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Malignant melanoma
  • Phase II Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Phase Unknown Pancreatic cancer

Most Recent Events

  • 23 Mar 2017 Incyte plans the ECHO-207 phase I/II trial for Solid tumours (Metastatic disease, Late-stage disease, Combination therapy, Second-line therapy or greater) in USA (NCT03085914)
  • 09 Jan 2017 Incyte and Merck plan phase III pivotal studies in Non-small cell lung cancer, Renal cell carcinoma, Bladder cancer and Head and neck cancer (Combination therapy)
  • 28 Dec 2016 Investigation in Pancreatic cancer in USA (PO) before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top